Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
30 Asthma Trials near Raleigh, NC
Power is an online platform that helps thousands of Asthma patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Triple Therapy for Uncontrolled Asthma
Raleigh, North CarolinaThe goal of this study is to assess and compare the effectiveness of fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (FF/UMEC/VI) with inhaled corticosteroids/long-acting beta-2 agonists (ICS/LABA) in adult participants with uncontrolled asthma
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Life-threatening Asthma, COPD, Others
Must Be Taking:ICS, ICS/LABA
1358 Participants Needed
Dexpramipexole for Eosinophilic Asthma
Raleigh, North CarolinaThis trial is testing an oral medication called dexpramipexole to help people with a type of asthma that isn't well controlled by their current treatments. The medication works by reducing specific white blood cells that cause inflammation, which may improve breathing and asthma control.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:12 - 99
Sex:All
550 Participants Needed
Budesonide + Formoterol Inhaler for Asthma
Raleigh, North CarolinaThis trial tests an inhaler that combines two medications to help people with poorly controlled asthma. It aims to see if this new inhaler can better manage their symptoms by reducing inflammation and keeping airways open. Combination products often have useful clinical benefits in asthma. The scientific rationale for combination therapy includes the fact that different agents have complementary modes of action.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:12 - 80
Sex:All
645 Participants Needed
Depemokimab for Asthma
Raleigh, North CarolinaThis trial is testing a new medication called Depemokimab for people with severe asthma who have high levels of certain white blood cells. The goal is to see if switching to Depemokimab works as well as their current treatments. The medication aims to reduce these white blood cells to help control asthma symptoms.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:12+
Sex:All
1719 Participants Needed
Fluticasone Propionate/Albuterol Sulfate for Asthma
Raleigh, North CarolinaThe primary objective of the trial is to evaluate the efficacy of fluticasone propionate/albuterol sulfate multidose dry powder inhaler with electronic module (Fp/ABS eMDPI).
Secondary objectives are:
* To evaluate the efficacy of Fp/ABS eMDPI administered four times daily
* To evaluate the safety and tolerability of Fp/ABS eMDPI administered four times daily over four weeks
* To investigate the pharmacokinetics of Fp/ABS eMDPI, ABS eMDPI and Fp eMDPI after administration of a single dose
The planned study duration for each participant is approximately 10 weeks, excluding an optional prescreening visit.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:12+
Sex:All
Key Eligibility Criteria
Disqualifiers:Life-threatening Asthma, Respiratory Infection, Smoking, Others
Must Be Taking:Beta-agonists
724 Participants Needed
New Propellant Inhaler for Asthma
Raleigh, North CarolinaThe purpose of this study is to assess the PD equivalence of the approved asthma combination therapy, BDA, delivered using the proposed replacement propellant HFO compared with BDA delivered using the currently approved propellant HFA in participants with asthma.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:COPD, Life-threatening Asthma, Others
Must Be Taking:Low-dose ICS, ICS-LABA
398 Participants Needed
Dexpramipexole for Asthma
Raleigh, North CarolinaThis trial is testing an oral medication called dexpramipexole in people with severe asthma that isn't well controlled by usual treatments. The medication aims to reduce certain cells in the blood that make asthma worse, helping to better manage symptoms.
Stay on current meds
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:12 - 99
Sex:All
Key Eligibility Criteria
Disqualifiers:Severe Asthma Exacerbation, COPD, Others
Must Be Taking:Inhaled Corticosteroids
1395 Participants Needed
Inhaled PT007 for Asthma
Raleigh, North CarolinaPhase II study, to investigate the therapeutic efficacy and safety of inhaled PT007 (referred to as AS MDI) compared with placebo MDI and open-label Ventolin Evohaler in male and female participants aged 18 to 65 years (inclusive) with asthma.
This study consists of a screening/run-in period, a treatment period, and a follow-up phone call.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:COPD, Life-threatening Asthma, Cancer, Others
Must Be Taking:SABA, ICS, LABA
102 Participants Needed
PT010 Inhaler for Asthma
Raleigh, North CarolinaThis is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:12 - 80
Sex:All
2266 Participants Needed
Inspiratory Muscle Training for Childhood Asthma
Durham, North CarolinaThis is a single-center, randomized, SHAM-controlled, parallel assignment, double-masked,8-week interventional study among children aged 8-17 years (not yet 18 years old) of age with obesity and asthma. (n=60), recruited from Duke Health Center Creekstone, to test the effectiveness of inspiratory muscle rehabilitation (IMR) as an acceptable add-on intervention to reduce dyspnea (feeling short-of-breath or breathless) and to promote greater activity in children with obesity and asthma.
Clinic to test the effectiveness of inspiratory muscle rehabilitation (IMR) as an acceptable add-on intervention to reduce dyspnea (feeling short-of-breath or breathless) and to promote greater activity in children with obesity
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:8 - 17
Sex:All
Key Eligibility Criteria
Disqualifiers:Prior Intubation, Pregnancy, FEV1 < 50%, Others
Must Be Taking:Albuterol, Inhaled Steroids
60 Participants Needed
Telehealthcare MTM for Asthma
Durham, North CarolinaThis trial uses video calls and sensors to help young people with asthma take their medication regularly. It targets those who struggle with sticking to their prescribed treatment, aiming to improve their health by providing support and reminders.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:12 - 35
Sex:All
300 Participants Needed
MART vs ICS Add-On for Asthma
Durham, North CarolinaThe goal of this trial test two known effective asthma strategies. Treatment guidelines recommend combination therapy of inhaled corticosteroids (ICS) with a long-acting beta-agonist (LABA) inhaled medications. This strategy is known as MART (maintenance and reliever therapy). The second strategy is PARTICS (patient activated reliever triggered ICS) strategy instructs patients to use an ICS metered dose inhaler (ICS) each time they use their rescue inhaler. In addition, they are instructed to take 5 puffs of the ICS after each rescue nebulizer use. PARTICS has been shown to reduce exacerbations, increase asthma control and quality of life, however, the question remains if PARTICS is as effective as MART and therefore be an alternative to MART. This trial will test PARTICS and MART head-to-head.
The trial will include adults with moderate-to-severe asthma at risk for an asthma exacerbation, currently using a combination ICS.
The main questions aim to answer:
* Is PARTICS as effective as SMART?
* Might PARTICS be more effective than SMART? Is the relative effectiveness of PARTICS versus SMART affected by frequent nebulizer use for asthma relief?
* Do PARTICS and SMART diverge in terms of their effectiveness on differing asthma outcomes important to patients?
* Do socioeconomic factors affect the relative effectiveness of PARTICS and SMART? Researchers will compare non frequent nebulizer (NFN) users - less than once a week to frequent nebulizer users - once a week or more, to assess whether the PARTICS strategy is ono-inferior (or superior to the MART strategy in reducing exacerbations, (primary outcome), increasing asthma control and quality of life and decrease days lost from work/school or usual activities.
Most participants will be consented, enrolled, and randomized virtually, others will be consented, enrolled and randomized in person. Once randomized they will be instructed on how to use the prescribed medication:
* Participants randomized to MART will be instructed to use the prescribed ICS/LABA for maintenance and as needed for rescue.
* Participants randomized to PARTICS will be instructed to use the prescribed ICS each time they use their rescue inhaler and take 5 puffs of the newly prescribed ICS after each rescue nebulizer use.
* Participants will be followed for 16 months by monthly survey.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:18 - 75
Sex:All
4100 Participants Needed
Fluticasone + Albuterol for Asthma
Chapel Hill, North CarolinaThis trial tests different doses of a combination of fluticasone and albuterol in an electronic inhaler for asthma patients. The goal is to reduce severe asthma attacks by decreasing lung inflammation and opening airways. Fluticasone is a potent anti-inflammatory medication, and albuterol helps to open airways.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:4+
Sex:All
Key Eligibility Criteria
Disqualifiers:Life-threatening Asthma, Recent CAE, Smoking, Others
Must Be Taking:Inhaled Asthma Controllers
2196 Participants Needed
Rocatinlimab for Asthma
Durham, North CarolinaThe primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Pulmonary Disease, Smoking, COVID-19, Others
Must Be Taking:Inhaled Corticosteroids
428 Participants Needed
Inspiratory Muscle Training for Childhood Asthma
Durham, North CarolinaThis is single-center cross-sectional mechanistic study in lean and obese children with moderate-severe asthma, followed by a randomized, SHAM-controlled trial of Inspiratory Training (IT). The primary outcome is to describe the contributions of inspiratory muscle dysfunction (IMD) and Small Airway Dysfunction (SAD) to obesity-related versus non-obesity-related asthma. The study will involve training (IT) for 8 weeks at three intensity levels (SHAM, low and high). Target dose: 150 inspirations three times weekly. The population includes 6 to 17-year-old children with moderate to severe asthma and with a body mass index qualifying as normal habitus (BMI 5th to 84th CDC percentile) or obese habitus (≥95th percentile BMI and less than 170% of the 95th CDC percentile). Participants will be involved for 10 weeks. The investigators will use analysis of covariance (ANCOVA) to estimate and test the difference in mean values of baseline measures between obese and non-obese cohorts. Covariates will include age, sex (male/female), race/ethnicity, baseline asthma severity (NAEPP step 2 vs ≥3), and atopy status
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:6 - 17
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Major Chronic Illness, Others
Must Be Taking:Controller Prescriptions
76 Participants Needed
OM-85 for Recurrent Wheezing
Chapel Hill, North CarolinaThis trial will test if daily OM-85 can reduce wheezing episodes in young children who often experience them. The study will focus on children aged 6 months to 5 years. OM-85 aims to help the immune system fight off infections that cause wheezing. OM-85 has been shown to reduce the risk of recurrent respiratory tract infections and wheezing attacks in children.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:6 - 72
Sex:All
Key Eligibility Criteria
Disqualifiers:Chronic Respiratory Diseases, Autoimmune, HIV, Others
Must Not Be Taking:Steroids, Immunosuppressants
288 Participants Needed
Oral Bacterial Extract for Wheezing
Chapel Hill, North CarolinaThis trial tests if giving Broncho-Vaxom® to high-risk infants can delay their first episode of wheezing illness. The medication is given regularly over a long period and aims to boost the immune system. The study focuses on infants aged 6-18 months who are more likely to develop asthma.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:6 - 18
Sex:All
822 Participants Needed
Genetic Screening for Inflammation Response to Wood Smoke Particles
Chapel Hill, North CarolinaPurpose: This screening protocol is designed to assess PMN (neutrophil) responsiveness to wood smoke particles (WSP) and the effect of the GSTM1 null genotype on this response. The researches will identify persons responsive and resistant to the inflammatory effect of WSP. It is anticipated that the GSTM1 genotype will be a risk factor for increased response to WSP.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 45
Sex:All
Key Eligibility Criteria
Disqualifiers:Cardiovascular Disease, Diabetes, Asthma, Others
Must Not Be Taking:Immunosuppressants, Anticoagulants, NSAIDs, Others
160 Participants Needed
Hyperpolarized 129XeMRI Imaging for Severe Asthma in Obesity
Durham, North Carolina40% of all asthma patients in the US are obese. Obese asthmatics have more severe disease than lean asthmatics and do not respond as well to conventional anti-inflammatory therapies. This proposal will utilize 3D functional imaging with 129XeMRI and single cell RNA sequencing to study mechanisms driving regional airway remodeling and fibrosis in obese asthma subjects and in preclinical models of obese asthma.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65
Sex:All
40 Participants Needed
Dupilumab for Asthma
Chapel Hill, North CarolinaThis is a parallel, Phase 3, 2-arm study to evaluate the efficacy and long-term safety of dupilumab treatment in children 2 to \<6 years of age with uncontrolled asthma and/or recurrent severe asthmatic wheeze. The study will be conducted in 2 parts. Part A will be a 52-week, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of dupilumab in children aged 2 to \<6 years old with uncontrolled asthma and/or recurrent severe asthmatic wheeze. At the end of Part A, all eligible participants will be offered participation in Part B, an optional open-label extension phase.
Study details include:
Part A:
The study duration of part A will be up to 68 weeks consisting of a 4-week Screening, a 52week treatment period, and a 12-week post-treatment follow-up period. For participants who will chose to participate in Part B, the study duration will be up to 120 weeks (additional 52-week treatment period).
Part B:
For participants who will choose to participate in Part B, the study duration will be up to 120 weeks (Part A \[4-week Screening and a 52-week treatment period\] plus additional 52-week treatment period and a 12-week post-treatment follow-up period).
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:2 - 5
Sex:All
Key Eligibility Criteria
Disqualifiers:Severe Asthma, Anaphylaxis, Prematurity, Others
Must Be Taking:Inhaled Corticosteroids
90 Participants Needed
Tezepelumab for Severe Asthma in Children
Chapel Hill, North CarolinaTo assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled corticosteroids (ICS) and at least one additional asthma controller medication with or without oral corticosteroids.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:5 - 11
Sex:All
Key Eligibility Criteria
Disqualifiers:Cystic Fibrosis, Chronic Rhinosinusitis, Others
Must Be Taking:Inhaled Corticosteroids
372 Participants Needed
Tezepelumab for Severe Asthma
Chapel Hill, North CarolinaThis trial tests an injectable medication called tezepelumab for people with severe asthma who need high doses of inhaled steroids and have frequent asthma attacks. The medication works by reducing inflammation in the airways to help improve breathing and decrease asthma attacks.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:12+
Sex:All
287 Participants Needed
Albuterol + Budesonide for Asthma
Greenville, North CarolinaANCHOR is a prospective, multi-center, phase IV, interventional, single-arm, open-label study of 2,000 adult participants with symptomatic asthma requiring the use of rescue therapy aimed to compare the asthma exacerbation rates before and after switching from albuterol or levalbuterol to albuterol plus budesonide inhalation aerosol as rescue therapy.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:COPD, Lung Cancer, Pregnancy, Others
Must Be Taking:Albuterol, Budesonide
2000 Participants Needed
PT010 Inhaler for Severe Asthma
Greensboro, North CarolinaThis trial tests an inhaler with three medications to help people with severe asthma who don't respond well to usual treatments. The inhaler reduces inflammation, relaxes muscles around the airways, and keeps them open longer. The study aims to see if this combination is more effective and safe compared to other treatments.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:12 - 80
Sex:All
2182 Participants Needed
Salbutamol Inhalers for Asthma
Winston-Salem, North CarolinaThe goal of this study is to assess and compare the safety and tolerability of salbutamol administered via metered dose inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in participants aged \>=18 years with asthma
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Life-threatening Asthma, Chronic Liver Disease, Others
Must Be Taking:Inhaled Corticosteroids, Short-acting Beta-agonists
412 Participants Needed
Dupilumab for Asthma
Winston-Salem, North CarolinaThis trial is testing dupilumab, a medication that reduces lung inflammation, in adults with moderate to severe asthma that isn't controlled by usual treatments. It aims to see if dupilumab can help improve breathing and slow down lung damage.
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18+
Sex:All
1324 Participants Needed
Depemokimab for Severe Asthma
Winston-Salem, North CarolinaThis trial is testing Depemokimab, a medication for people with severe asthma that doesn't respond well to usual treatments. It works by reducing specific cells that cause airway inflammation, aiming to improve breathing and reduce symptoms.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:12+
Sex:All
641 Participants Needed
Solriktug for Asthma
Winston-Salem, North CarolinaPhase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solriktug with adult participants with asthma.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Smoking, Cardiovascular, Pulmonary, Others
Must Be Taking:Inhaled Corticosteroids, Long-acting Beta Agonists
84 Participants Needed
AZD4604 for Asthma
Winston-Salem, North CarolinaThis trial tests a new asthma medication called AZD4604, which is inhaled regularly using a dry-powder inhaler. It targets adults whose moderate-to-severe asthma is not well-controlled by current treatments. The medication likely works by opening up the airways and reducing inflammation, making it easier to breathe.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:Severe Asthma Exacerbation, COVID-19, Others
Must Be Taking:ICS, LABA
320 Participants Needed
AZD8630 for Uncontrolled Asthma
Winston-Salem, North CarolinaA dose range-finding study to assess the efficacy and safety of multiple dose levels of AZD8630 administered via a dry powder inhaler in adults with uncontrolled asthma at risk of exacerbations, receiving medium -to -high dose inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA).
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:COPD, HIV, Cancer, Others
Must Be Taking:Inhaled Corticosteroids, Long-acting Β2-agonists
516 Participants Needed
Page 1 of 1+
Frequently Asked Questions
How much do Asthma clinical trials in Raleigh, NC pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Asthma clinical trials in Raleigh, NC work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Asthma trials in Raleigh, NC 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Raleigh, NC for Asthma is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Raleigh, NC several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Asthma medical study in Raleigh, NC ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Asthma clinical trials in Raleigh, NC ?
Most recently, we added Inhaled PT007 for Asthma, Fluticasone Propionate/Albuterol Sulfate for Asthma and MART vs ICS Add-On for Asthma to the Power online platform.